Image

Novel Targetable BIOmarkers in ANorexia NervosA

Novel Targetable BIOmarkers in ANorexia NervosA

Recruiting
18-60 years
All
Phase N/A

Powered by AI

Overview

The overall aim of this present study is to evaluate Growth Differentiation Factor-15 (GDF-15) and inflammatory cytokines as a possible novel and readily treatable target for the successful therapy of Anorexia Nervosa (AN). Therefore, GDF-15, neuronal and glial damage markers such as Neurofilament light chain (Nfl) and Glial fibrillary acidic protein (GFAP) and cytokines (such as Tumor necrosis factor alpha (TNF-α), Interleukin-6 (IL-6), and Interleukin 1β (IL-1β) levels will be assessed in the serum as well as in the cerebrospinal fluid of patients with diagnosed restrictive AN with and without exercising behavior compared to sex- and age-matched healthy controls to consolidate previous findings and to identify the main site of production of GDF-15 and cytokines in AN.

Description

In addition, assessment of body composition via Dual Energy X-ray Absorptiometry (DEXA )scans and of energy expenditure via indirect calorimetry, respectively, will allow us to correlate GDF-15, Nfl and GFAP and cytokine levels with lean and fat mass measures as well as with energy expenditure, respectively, of AN patients and the matched controls. Overall, this will allow us to comprehensively evaluate GDF-15 and cytokines as possible novel targets for the treatment of AN and to set the basis for a follow up study using available neutralizing antibodies or inhibitors against GDF-15 and the respective cytokines for the treatment of patients with AN, respectively. This will also allow for a more tailored, individualized treatment approach of AN in the future. Our findings will hopefully challenge the viewpoint that AN is a condition which can be controlled by the individual but demonstrate that AN is a biological disease that should be treated by targeting the right biological players in addition to psychiatric treatment.

Eligibility

N=8 adult male and female patients with confirmed diagnosis of anorexia nervosa restrictive

type, non-exercising subtype

Inclusion criteria:

  • Age 18-60 years
  • Written informed consent
  • BMI 10-16 kg/m2
        N=8 adult male and female patients with confirmed diagnosis of anorexia nervosa restrictive
        type, exercising subtype will be included in this study.
        Inclusion criteria:
          -  Age 18-60 years
          -  Written informed consent
          -  BMI 10-16 kg/m2
        N=16 control participants, sex- and age-matched to the individual anorexia nervosa
        patients.
        Inclusion criteria:
          -  Age 18-60 years
          -  Written informed consent
          -  BMI 19-24.9 kg/m2
        Exclusion Criteria:
          -  Use of antibiotics within the last 31 days
          -  Current illicit drug abuse including daily marijuana or CBD (cannabidiol) consumption
             (≤ 24 g of alcohol per day allowed)
          -  Any kind of severe chronic disease other than AN (e.g. active cancer disease)
          -  Severe renal impairment (e.g. estimated glomerular filtration rate <30 ml/min/m2) if
             resulting from another disease than AN
          -  Known liver cirrhosis or other severe liver impairment if resulting from another
             disease than AN
          -  Acute upper respiratory tract infection within the last 31 days
          -  Uncontrolled dysthyroidism
          -  Uncontrolled hypertension
          -  Current pregnancy/lactation or current treatment for in vitro fertilization
          -  Inability to understand the study information, to sign the consent form and to follow
             the procedures of the study, e.g. due to language problems, psychological disorders,
             dementia, etc.

Study details
    Anorexia Nervosa
    Anorexia Nervosa Restricting Type

NCT05885724

University Hospital, Basel, Switzerland

28 January 2024

Step 1 Get in touch with the nearest study center
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

  Other languages supported:

First name*
Last name*
Email*
Phone number*
Other language

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.